2024 APFPR ANNUAL REPORT HIGHLIGHTS
ACTIVITY
- APFPR aims to monitor outcomes of patients who have surgery for female Stress Urinary Incontinence (SUI) of Pelvic Organ Prolapse (POP) procedures, including those involving mesh or other products.
- Participation in the APFPR is voluntary for surgeons and hospitals. Participation for patients is also voluntary with 3.6% of those who are added to the database choosing to opt out.
- The annual report includes data up until the end of 2024:
- 53 hospitals were approved to participate (29 public and 24 private)
- Data is included from over 1,300 patients; 1,400 procedures and 1,100 products.
- The registry collects information regarding:
- All SUI procedures, most of which are mesh slings (60%) and bulking agents (26%)
- POP procedures that involve the insertion or removal of mesh. This is a smaller group of patients.
OUTCOMES FOLLOWING FIRST TIME PROCEDURES
- The majority of people (89%) having their first procedure for SUI experience early improvement in their symptoms, with approximately 4% requiring readmission within 30 days.
- 99% of people who had their first procedure for POP experienced early improvement in their symptoms with near – zero returning to hospital.
- The majority of people reported that their improvement in symptoms remained at 24 months.
- Outcomes have improved and complications are lower following SUI and POP procedures compared to when the registry began to collect data (three years prior).
MESH REMOVAL
- The majority of women who required mesh excision following a SUI mesh procedure presented with pain/tenderness (67%) and/or mesh exposure (59%) and/or Overactive Bladder Syndrome (23%).
- The majority of women who required mesh excision following a POP mesh procedure presented with mesh exposure (82%) and/or pain/tenderness (69%) and/or Overactive Bladder Syndrome (26%).
Please note more detailed information is available in the 2024 APFPR Annual Report.